Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Primary Spinal Malignant Mesothelioma: A Case Report and Literature Review.

Chen F, Liu B, Yu Y, Du J, Chen D.

World Neurosurg. 2018 Jun;114:211-216. doi: 10.1016/j.wneu.2018.03.124. Epub 2018 Mar 26. Review.

PMID:
29588242
2.

18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.

Elliott HS, Metser U, de Perrot M, Cho J, Bradbury P, Veit-Haibach P, Hussey D, Noam T.

Br J Radiol. 2018 Jun;91(1086):20170814. doi: 10.1259/bjr.20170814. Epub 2018 Mar 29.

PMID:
29498536
3.

Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial.

Stewart SA, Clive AO, Maskell NA, Penz E.

PLoS One. 2018 Feb 5;13(2):e0190257. doi: 10.1371/journal.pone.0190257. eCollection 2018.

4.

Radical multimodality therapy for malignant pleural mesothelioma.

Abdel-Rahman O, Elsayed Z, Mohamed H, Eltobgy M.

Cochrane Database Syst Rev. 2018 Jan 8;1:CD012605. doi: 10.1002/14651858.CD012605.pub2. Review.

PMID:
29309720
5.

Neoplastic Pericardial Disease.

Maleszewski JJ, Anavekar NS.

Cardiol Clin. 2017 Nov;35(4):589-600. doi: 10.1016/j.ccl.2017.07.011. Epub 2017 Sep 6. Review.

PMID:
29025549
6.

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.

Burt BM, Lee HS, Lenge De Rosen V, Hamaji M, Groth SS, Wheeler TM, Sugarbaker DJ.

Ann Thorac Surg. 2017 Nov;104(5):1679-1687. doi: 10.1016/j.athoracsur.2017.06.042. Epub 2017 Sep 28.

PMID:
28964420
7.

Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.

Mansour MSI, Seidal T, Mager U, Baigi A, Dobra K, Dejmek A.

Cancer Cytopathol. 2017 Dec;125(12):908-917. doi: 10.1002/cncy.21917. Epub 2017 Sep 18.

PMID:
28922567
8.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G.

J Clin Oncol. 2017 Nov 1;35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012. Epub 2017 Sep 11.

9.

Radiotherapy for the treatment of malignant pleural mesothelioma.

Perrot M, Wu L, Wu M, Cho BCJ.

Lancet Oncol. 2017 Sep;18(9):e532-e542. doi: 10.1016/S1470-2045(17)30459-X. Review.

PMID:
28884702
10.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.

Lancet Oncol. 2017 Oct;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6. Epub 2017 Sep 1.

PMID:
28870611
11.

The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.

Ashton M, O'Rourke N, Currie S, Rimner A, Chalmers A.

Radiother Oncol. 2017 Oct;125(1):1-12. doi: 10.1016/j.radonc.2017.08.003. Epub 2017 Aug 28. Review.

PMID:
28859932
12.

Diagnostic Imaging and workup of Malignant Pleural Mesothelioma.

Cardinale L, Ardissone F, Gned D, Sverzellati N, Piacibello E, Veltri A.

Acta Biomed. 2017 Aug 23;88(2):134-142. doi: 10.23750/abm.v88i2.5558. Review.

PMID:
28845826
13.

Regulation of microRNA using promising dietary phytochemicals: Possible preventive and treatment option of malignant mesothelioma.

Sayeed MA, Bracci M, Lucarini G, Lazzarini R, Di Primio R, Santarelli L.

Biomed Pharmacother. 2017 Oct;94:1197-1224. doi: 10.1016/j.biopha.2017.07.075. Epub 2017 Aug 23. Review.

PMID:
28841784
14.

Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.

Chandramohan A, Thrower A, Shah N, Mohamed F.

Br J Radiol. 2017 Nov;90(1079):20170361. doi: 10.1259/bjr.20170361. Epub 2017 Aug 22.

PMID:
28830230
15.

Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.

Facchetti G, Petrella F, Spaggiari L, Rimoldi I.

Eur J Med Chem. 2017 Dec 15;142:266-270. doi: 10.1016/j.ejmech.2017.07.063. Epub 2017 Aug 2. Review.

PMID:
28800871
16.

The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Marchevsky AM, LeStang N, Hiroshima K, Pelosi G, Attanoos R, Churg A, Chirieac L, Dacic S, Husain A, Khoor A, Klebe S, Lantuejoul S, Roggli V, Vignaud JM, Weynard B, Sauter J, Henderson D, Nabeshima K, Galateau-Salle F.

Hum Pathol. 2017 Sep;67:160-168. doi: 10.1016/j.humpath.2017.07.015. Epub 2017 Aug 4. Review.

PMID:
28782639
17.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

PMID:
28777143
18.

Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.

O'Hara MH, Stashwick C, Plesa G, Tanyi JL.

Immunotherapy. 2017 Aug;9(9):767-780. doi: 10.2217/imt-2017-0026. Epub 2017 Aug 3. Review.

PMID:
28771103
19.

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA.

Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Review.

PMID:
28740119
20.

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.

Calabrò L, Ceresoli GL, D'Incecco A, Scherpereel A, Aerts J, Maio M.

Cytokine Growth Factor Rev. 2017 Aug;36:25-31. doi: 10.1016/j.cytogfr.2017.07.003. Epub 2017 Jul 12. Review.

PMID:
28736182

Supplemental Content

Loading ...
Support Center